Market research
SUNPHARMA.NSE Sun Pharmaceutical Industries Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 5T
- P/E ratio
- 37.89
- Analyst target
- 2167.2122
- Dividend yield
- 0.0%
- Beta
- 0.12
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE044A01036
- Market cap
- 5T
- P/E ratio
- 37.89
- Analyst target
- 2167.2122
- Dividend yield
- 0.0%
- Beta
- 0.12
About
About Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; specialty medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers generics and APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SUNPHARMA.NSE discussion.
5 years, 5 months ago
Sun Pharmaceutical Industries Limited is currently in a long term uptrend where the price is trading 13.6% above its 200 day moving average.
From a valuation standpoint, the stock is 8.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.4.
Sun Pharmaceutical Industries Limited's total revenue rose by 7.7% to $88B since the same quarter in the previous year.
Its net income has increased by 102.8% to $19B since the same quarter in the previous year.
Finally, its free cash flow fell by 48.4% to $19B since the same quarter in the previous year.
Based on the above factors, Sun Pharmaceutical Industries Limited gets an overall score of 4/5.